Tranzyme Pharma to present ulimorelin Phase 2 data at NGM Meeting

Tranzyme Pharma announced today that John Wo, MD, Professor of Medicine, Director, Clinical Research, Division of Gastroenterology, Hepatology and Nutrition, University of Louisville, Louisville, KY, will present ulimorelin Phase 2 data at this year's Joint International NGM Meeting on Saturday, August 28, 2010. The conference is being held at the Westin Copley Place in Boston, MA. Professor Wo is scheduled to speak at 11:00am during Oral Session 3.

“Ulimorelin (ghrelin agonist) effects on daily vomiting due to diabetic gastroparesis”

The presentation entitled, "Ulimorelin (ghrelin agonist) effects on daily vomiting due to diabetic gastroparesis" will summarize the effects of ulimorelin in subjects with daily, moderate to severe vomiting.

Gastroparesis, in severe cases, can be responsible for frequent hospitalizations and emergency room admissions due to recurrent nausea and vomiting, which may be associated with dehydration, malnutrition and weight loss due to inadequate caloric food intake. Currently, there are no safe and effective treatments for gastroparesis. Earlier prescription medications used to treat this condition were either withdrawn from the market or must carry a "black box" warning due to serious side effects.

In Tranzyme's Phase 2 study of diabetic patients with advanced gastroparesis, ulimorelin, given intravenously once daily for four days, demonstrated clinically and statistically significant improvements in multiple gastroparesis-related symptoms, including vomiting and nausea.

Patients who had moderate to severe daily vomiting during the 4 day run-in period (just prior to the study start), reported a marked reduction in the number of days with vomiting during the subsequent 4-day treatment period.

Source : Tranzyme Pharma